BioLargo (BLGO) 10-Q2015 Q1 Quarterly report

Content analysis

Filed: 15 May 15, 12:00am

Dated: May 15, 2015

/s/ DENNIS P. CALVERT

Dennis P. Calvert

President and Chief Executive Officer

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: AG, anchor, annum, APVMA, ash, Australian, automated, bacteria, bearing, begun, big, biocide, biological, break, budget, calibrated, center, chlorine, credible, cumulative, deciding, depth, discount, diverse, ecoli, eligible, Expo, feature, featuring, fire, flexibility, forever, formula, forourSpecimen, framework, FSANZ, fungal, fungi, HACCP, Hazard, IDPO, incidence, increasingly, interface, intrinsic, introduced, invention, irrigation, launch, logical, long, lose, maximum, molecule, monitoring, oxygen, pharmaceutical, physical, platform, primitive, Reay, relationship, reliability, revalued, sacrificing, salt, sanitation, shelf, shipyard, simple, skilled, spoilage, steam, stringent, student, superseding, supplement, supplier, talent, threaten, tracking, trade, trading, turn, unamortized, understood, unmatched, unsecured, user, vast, winner, wood

Removed: account, accurate, active, actively, advantage, approval, area, array, assisted, balance, Biotech, breadth, care, catalyst, CFI, ChemBioMed, clean, combine, commercially, consistent, consuming, convert, core, CRC, dated, dedicated, directly, disease, dismantling, dose, Dr, earth, edge, effectively, efficiency, efficient, embodied, environmentally, equipment, essential, experience, extend, extending, familiar, FDA, feel, fellowship, forward, free, Gamal, generation, goal, guide, hand, healing, healthy, highest, hoped, Immunology, Immunopathology, impacted, implementation, improve, infection, ingredient, innovative, involved, iv, joined, lead, leveraging, manner, marketplace, metabolic, microbial, microbiology, modified, Mohamed, moisture, MSc, nominal, NSERC, nutrient, offer, office, opened, oxidizing, partially, patented, pathway, people, pervasive, PhD, pilot, precision, present, President, producing, program, promote, range, ranging, refining, represent, require, requirement, resistance, retained, roll, safer, Saskatchewan, segment, sensitive, slower, staining, strategy, suite, target, tender, timing, toxic, traditional, treatment, ultimate, Viral, VirRexx, wide, winter, wound

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

BLGO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Dennis P. Calvert, Chief Executive Officer of BioLargo, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that the Quarterly Report of BioLargo, Inc. on Form 10-Q for the quarter ended March 31, 2015 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of BioLargo, Inc.

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to BioLargo, Inc. and will be retained by BioLargo, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

I, Charles K. Dargan II, Chief Financial Officer of BioLargo, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that the Quarterly Report of BioLargo, Inc. on Form 10-Q for the quarter ended March 31, 2015 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of BioLargo, Inc.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.